ABSTRACT
or reducing complications. The present aim was to evaluate cases of snakebite in terms of clinical stage, complications, treatment modalities, and clinical termination of treatment in patients who presented to the emergency department.
MATERIALS AND METHODS
Records of 132 patients who presented with snakebite were retrospectively analyzed. All patients were evaluated in terms of age, gender, site of bite, local and systemic complications, clinical stages (Table 1) , treatment, and results. [2] All laboratory findings were collected from the laboratory information system and are shown in Table 2 .
All patients were evaluated, and antivenom therapy was administered according to clinical stage. European viper antiserum provided by Turkey's Health Ministry was used (10-mL flacon, administered intramuscularly or intravenously, or 100 mg/mL horse immunoglobulin), in addition to 1 mg/kg steroid, 1 mg/kg pheniramine, and 1 mg/kg ranitidine, initiated for allergenic prophylaxis. Antivenom was administered by intravenous controlled infusion with 100 cc of serum physiologic in 60 min. Data were analyzed using SPSS software (version 21.0; SPSS Inc., Chicago, IL, USA).
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INTRODUCTION
Snakebite is a very serious health risk in tropical regions. It is estimated that Turkey hosts 40 species of snakes, though Viperidae are the most common. Snakebites may present with various clinical manifestations, including mild local symptoms, systemic complications, and death. [1, 2] Level of toxicity depends upon several factors, including type and amount of venom injected, location of the bite, and sensitivity of the patient to poison. Graded clinical staging has been developed in order to facilitate treatment and monitorization. [2] Treatment is administered according to clinical stage, preventing
RESULTS
Thirty-one (23.1%) female and 101 (76.5%) male patients aged between 3 and 84 years were enrolled. The site of 71 (54.2%) bites was an upper extremity, the site of 60 (45.4%) was a lower extremity, the site of 1 was the neck. Clinically graded stages were as follows: 57 (42.9%) cases were grade 0; 38 (28.6%) cases were grade I; 29 (22%) cases were grade II; and 8 (6.5%) cases were grade III.
Local complications were observed at all stages; systemic complications were observed only at advanced stages. The most common local complication was pain (n=56, 42.4%) ( Table 3 ). In laboratory evaluation, routine parameters were analyzed. Serum glucose levels, alanine aminotransferase and aminotransferase activities, and sodium and potassium levels were normal. All echocardiograms showed normal activity. Mean Glasgow Coma Scale scores of patients were 14-15 (Table 4) . Prothrombin time (PT) and partial thromboplastin time (PTT) were prolonged, compared to control levels measured 12 hours later.
Increased white blood cell (WBC >10.2x10 3 /µL) counts were detected in 44 patients at time of admission, while leukocytosis was detected in 18 patients during control evaluation.
However, no significant relationship between WBC counts and clinical stages was determined. Erythrocyte suspension was administered for patients with hemoglobin values below 
Monitoring
The patient can be discharged after 8 hours of monitoring.
The patient can be discharged after 12 hours of monitoring.
The patient should be monitorized closely during therapy.
The patient should be monitored in the intensive care unit. Table 5 .
Sixty-nine (52.2%) patients were hospitalized, 3 of whom had grade III bites and were transferred to the intensive care unit. Sixty-three patients were monitored in the emergency department, where no complications were observed and the bites were considered to be grade 0. These patients were discharged following 6 hours of monitoring. No mortality was observed, and no complications were observed during the 1-year monitoring period.
DISCUSSION
Snake venom can cause a variety of clinical conditions, according to the type and amount of toxin, the type of snake, and the susceptibility of the patient. Patients are treated and monitored according to clinical grading. [2] Snake venom has various toxic effects on the region of the bite and on the entire body, including local complications such as pain and swelling at the site, edema, erythema, necrosis, and cellulitis, as well as systemic complications such as fever, nausea and vomiting, compartment syndrome, heart failure, arrhythmias, acute renal failure, shock, coma, or death (Fig. 1a-c) . [3, 4] Patients are treated according to recommended protocols. Dry bites without envenomation are scored as grade 0, and bites that lack systemic signs or symptoms are scored as grade I. Antibiotherapy, tetanus vaccine, and symptomatic therapy are administered in these cases.
Antivenom is the main treatment option in cases of venomous snakebite. [5, 9] Rate of antivenom therapy ranges from 16-80%. [1, 5, 6] Antivenom therapy should be administered to patients with advancing local or systemic complications. In a study conducted by Karakuş et al., the rate of complication was reported as 2.4%, while rates ranging between 20-75% have been reported elsewhere. [1, 5, [7] [8] [9] In the present emergency department, antivenom therapy was administered to 61 (46.4%) patients, all of whom had grade II or III bites. Anaphylactic reaction due to antivenom administration was observed in only 2 patients. However, they were discharged following improvement, which may have been the result of administration of steroid and antihistaminic therapy for prophylaxis prior to antivenom administration.
Snake venom includes a variety of toxins and consists of 70% water and 30% protein substances, including leukotrienes, phospholipases, acetylcholinesterase, hyaluronidase, collagenase, antibactericides, neurotoxins, hemotoxins, anticoagulants, cardiotoxins, hemolytic factors, fibrinolytic enzymes, quinine, and histamine. [10, 11] Toxins can cause diverse systemic effects, such as leukocytosis, thrombocytopenia, hypofibrinogenemia, bleeding disorders, proteinuria, and azotemia. [4, 12, 13] However, leukocytosis has been primarily reported as a laboratory finding. [5, 14] The most common venomous snakes in Turkey have neurotoxins and hemotoxins, and belong to the Viperidae family. [4] In the present study, bleeding disorder and anemia were the most common systemic complications. Antivenom and erythrocyte suspension were administered. Daily hemogram, and PT, PTT, and international normalized ratio (INR) monitoring can aid in the prevention of complications.
Patients should be evaluated according to grade of bite and clinically treated. Patients with grade 0 or I bites, with no systemic complications, can be discharged after 12 hours of monitoring. [2, [15] [16] [17] Symptomatic treatment should be administered. Death can result from insufficient therapy. According to the World Health Organization, about 35000-50000 people die annually from snakebites. [2] In the present study, 69 (52.2%) patients were hospitalized, and 63 (47.7%) were discharged following improvement after 6-12 hours of monitoring. No deaths or negative outcome were observed during 1-year follow-up, the result of accurate clinical grading, monitoring, and treatment.
Conclusions
Complications resulting from toxins of snake venom should be evaluated, and appropriate treatment should be efficiently administered according to snakebite grade. Patients should be monitored with daily hemogram and bleeding diathesis tests.
We believe that this approach may prevent or decrease the number of complications.
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